Xingli Taike: Signs Agreement with Novo Shengtai, Obtains Exclusive License Rights for STC007

People’s Financial News, March 20 — Xinyi Tai (002294) announced on March 20 that the company plans to sign an agreement with Chengdu Nuoheshengtai Biotechnology Co., Ltd. (referred to as “Nuoheshengtai”) to acquire the intellectual property rights and licensing technology related to the raw materials and formulations of STC007 (referred to as “STC007”) for all itch-related indications in the Chinese market. This includes but is not limited to product research and development, registration, production, and commercialization. The company will make payments using self-raised funds based on the progress of the transaction and R&D developments. The total amount of the initial payment and R&D milestone payments will not exceed 125 million yuan. If the product is approved for market sale and the net sales (measured by calendar year) first reach the amount specified in the agreement, the company will pay sales milestone payments, with a maximum cumulative sales milestone of 725 million yuan. Additionally, within the period specified in the agreement, the company will pay Nuoheshengtai a sales commission based on a certain percentage of annual net sales.